Champion of Covid tests during the pandemic, Eurofins has difficulty digesting the exhaustion of this windfall.
In 2023, the French group, now listed on the CAC 40, has not managed to completely compensate for the shortfall linked to the collapse in the number of PCR tests carried out in medical analysis laboratories, in hospitals, or in company.
Its turnover fell by almost 3% in 2023, to 6.5 billion euros, while its net profit was halved, to 308 million euros.
The generous reimbursements granted by the State to encourage players to carry out PCR tests no longer support the group's profitability, while the war in Ukraine has, on the contrary, caused its costs to soar.
Eurofins had anticipated these changes and lowered its forecasts during the summer.
The French group's action nonetheless fell by 6.65% this Tuesday.
Biological tests, only 20% of its turnover
For Eurofins, the step was high.
During the pandemic, this family group, still led by its founder, changed…
This article is reserved for subscribers.
You have 80% left to discover.
Do you want to read more?
Unlock all items immediately.
TEST FOR €0.99
Already subscribed?
Log in